This review covers the development of multi-agonist therapies, including GLP-1glucagon and GIPGLP-1glucagon receptor agonists, which represent a significant advancement in obesity treatment
Last reviewed: May 30, 2026 Last updated: May 30, 2026 Written by: Jay Hastings , CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
the one or more hepatocyte growth factor mimics have a general structural formula , -R 3 -R 3 -NH-(CH 2 ) ir C-NH 2 i is one of an N-acyl group, a substituted or unsubstituted phenyl, a norleucine group, and an amino acid selected from tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine norvaline, ornithine, and s-benzyl cysteine
doi: 10.3389/fphar.2022.969107 Received 14 June 2022 Accepted 12 September 2022 Published 03 October 2022 Volume 13 - 2022 Edited by Dan-Qian Chen, Northwest University, China Updates Copyright 2022 Chen, Ye, Wang, Liu, Wang, Wang, Xu and Gong